Galapagos NV (FRA:GXEA)

Market Cap	1.82B
Revenue (ttm)	286.92M
Net Income (ttm)	-435.96M
Shares Out	n/a
EPS (ttm)	-6.62
PE Ratio	n/a
Forward PE	8.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Average Volume	34
Open	26.80
Previous Close	26.60
Day's Range	26.80 - 27.00
52-Week Range	19.90 - 31.40
Beta	n/a
RSI	50.58
Earnings Date	Feb 23, 2026

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 704
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GXEA

Financial Performance

In 2024, Galapagos NV's revenue was 275.65 million, an increase of 14.99% compared to the previous year's 239.72 million. Earnings were 74.08 million, a decrease of -65.01%.